da Veiga CR - Search Results

1

Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

da Veiga CP, da Veiga CR, Del Corso JM, da Silva WV. da Veiga CP, et al. Among authors: da veiga cr. Int J Environ Res Public Health. 2015 Aug 12;12(8):9454-74. doi: 10.3390/ijerph120809454. Int J Environ Res Public Health. 2015. PMID: 26274968 Free PMC article.

2

Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.

da Veiga CRP, da Veiga CP, Drummond-Lage AP. da Veiga CRP, et al. Crit Rev Oncol Hematol. 2018 Sep;129:133-145. doi: 10.1016/j.critrevonc.2018.07.002. Epub 2018 Jul 17. Crit Rev Oncol Hematol. 2018. PMID: 30097232 Review.

3

Cutaneous melanoma: cost of illness under Brazilian health system perspectives.

da Veiga CRP, da Veiga CP, Souza A, Wainstein AJA, de Melo AC, Drummond-Lage AP. da Veiga CRP, et al. BMC Health Serv Res. 2021 Mar 29;21(1):284. doi: 10.1186/s12913-021-06246-1. BMC Health Serv Res. 2021. PMID: 33781270 Free PMC article.

4

Attitude and Purchase Intention to Generic Drugs.

Arcaro R, da Veiga CRP, da Silva WV, Pereira da Veiga C. Arcaro R, et al. Among authors: da veiga crp. Int J Environ Res Public Health. 2021 Apr 26;18(9):4579. doi: 10.3390/ijerph18094579. Int J Environ Res Public Health. 2021. PMID: 33925923 Free PMC article.

5

Social Media Analysis to Understand the Expected Benefits by Plant-Based Meat Alternatives Consumers.

Moreira MNB, da Veiga CRP, Su Z, Reis GG, Pascuci LM, da Veiga CP. Moreira MNB, et al. Among authors: da veiga crp. Foods. 2021 Dec 18;10(12):3144. doi: 10.3390/foods10123144. Foods. 2021. PMID: 34945694 Free PMC article.

6

Does it fit in your pocket? economic burden of PD-1 inhibitors' toxicity in the supplementary health system: evidence from Brazil.

Duarte HS, da Veiga CRP, da Veiga CP, Wainstein AJA, da Silva WV, Drummond-Lage AP. Duarte HS, et al. Among authors: da veiga crp. BMC Health Serv Res. 2023 Jul 21;23(1):781. doi: 10.1186/s12913-023-09736-6. BMC Health Serv Res. 2023. PMID: 37480058 Free PMC article.

7

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.

Engel Ayer Botrel T, Datz Abadi M, Chabrol Haas L, da Veiga CRP, de Vasconcelos Ferreira D, Jardim DL. Engel Ayer Botrel T, et al. Among authors: da veiga crp. J Med Econ. 2021 Jan-Dec;24(1):291-298. doi: 10.1080/13696998.2021.1883034. J Med Econ. 2021. PMID: 33538203 Free article.

8

Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer.

Paladini L, da Veiga CRP, Cerqueira É, Chabrol Haas L, Datz Abadi M, Baldotto CS. Paladini L, et al. Among authors: da veiga crp. J Med Econ. 2021 Jan-Dec;24(1):1185-1193. doi: 10.1080/13696998.2021.1993864. J Med Econ. 2021. PMID: 34647849 Free article.

9

Advancing nursing education in Brazil: A systematic literature review of curricular evolution and emerging challenges.

da Veiga CRP, de Moraes ALL, Marques VG, da Silva DM, da Veiga CP. da Veiga CRP, et al. Nurse Educ Today. 2024 Apr 26;139:106228. doi: 10.1016/j.nedt.2024.106228. Online ahead of print. Nurse Educ Today. 2024. PMID: 38696884 Review.

10

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: The regulatory journey in Brazil.

da Veiga CRP, da Veiga CP, Machado E, Drummond-Lage AP. da Veiga CRP, et al. Crit Rev Oncol Hematol. 2023 Dec;192:104138. doi: 10.1016/j.critrevonc.2023.104138. Epub 2023 Sep 20. Crit Rev Oncol Hematol. 2023. PMID: 37739145 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page